journal
MENU ▼
Read by QxMD icon Read
search

Clinical Neuropharmacology

journal
https://www.readbyqxmd.com/read/27879551/no-superiority-of-treatment-with-osmotic-controlled-release-oral-delivery-system-methylphenidate-over-short-medium-acting-methylphenidate-preparations-in-the-rate-and-timing-of-injuries-in-children-with-attention-deficit-hyperactivity-disorder
#1
Pavel Golubchik, Arad Kodesh, Abraham Weizman
OBJECTIVES: Methylphenidate (MPH) treatment in patients with attention-deficit/hyperactivity disorder (ADHD) is reported to reduce the risk for injuries. In the present study, the rate and timing of injuries were compared among the various MPH preparations (4 and 6-8 vs 12 hour-acting) in children with ADHD. METHODS: This real-world retrospective study covered the years 2011 to 2013. Participants included 2042 youngsters (aged 4-18 years, 13.01 ± 3.2 years; 71...
November 22, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879550/successful-treatment-of-brachial-plexopathy-due-to-herpes-zoster-infection-with-intravenous-immunoglobulin
#2
Michel Sáenz-Farret, Valeria Sandoval-Rodríguez, Claudia Esther Paz-Navarro, Carlos Zúñiga-Ramírez
OBJECTIVE: The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD: We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease who came to our hospital complaining of pain, skin lesions, and strength loss in his right arm during the past 2 months. Physical examination revealed vesicular rash compatible with varicella-zoster virus lesions...
November 22, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879549/fingolimod-use-for-the-treatment-of-multiple-sclerosis-in-a-clinical-practice-setting-in-madrid
#3
Victoria Galán Sánchez-Seco, Ignacio Casanova-Peño, Roberto Álvarez-Lafuente, Mónica Sánchez-Jiménez, Ángel García-Martínez, María Inmaculada Domínguez-Mozo, Ana María Arias-Leal, Marta García-Montojo, Rafael Arroyo-González
OBJECTIVE: To assess the effectiveness and safety of fingolimod use in a Spanish clinical practice setting. METHODS: Retrospective study with multiple sclerosis patients who received at least 1 fingolimod dose between January 2004 and January 2015. Effectiveness and safety data were collected during the entire treatment of each patient. Analysis was performed for the total population and stratified according to prior treatment, sex, and age at treatment initiation...
November 22, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27879548/switching-l-dopa-therapy-from-pulsatile-to-pulse-administration-reduces-motor-complications-in-parkinson-s-disease
#4
Giovanni Mostile, Alessandra Nicoletti, Valeria Dibilio, Antonina Luca, Loredana Raciti, Giorgia Sciacca, Calogero Edoardo Cicero, Rosario Vasta, Giulia Donzuso, Donatella Contrafatto, Mario Zappia
OBJECTIVE: To evaluate the severity of wearing-off and dyskinesia in patients with complicated Parkinson disease (PD) after switching L-dopa oral therapy from a "pulsatile" administration, consisting in intermittent multiple daily small doses of the drug, to a "pulse" administration, consisting in standard oral doses given at specific interdose intervals. METHODS: Thirty-four PD patients with motor complications were monitored twice with standardized waking day motor status evaluations using the Unified Parkinson Disease Rating Scale-Motor Examination (UPDRS-ME) and the Abnormal Involuntary Movement Scale (AIMS) after switching L-dopa administration modality from "pulsatile" to "pulse...
November 22, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764051/quality-of-life-and-functioning-in-comorbid-posttraumatic-stress-disorder-and-major-depressive-disorder-after-treatment-with-citalopram-monotherapy
#5
Alexander J Steiner, Nathalie Boulos, James Mirocha, Stephanie M Wright, Katherine L Collison, Waguih W IsHak
OBJECTIVES: Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) often have high comorbidity, consequently influencing patient-reported outcomes of depressive symptom severity, quality of life (QOL), and functioning. We hypothesized that the combined effects of concurrent PTSD and MDD would result in worse treatment outcomes, whereas individuals who achieved MDD remission would have better treatment outcomes. METHODS: We analyzed 2280 adult participants who received level 1 treatment (citalopram monotherapy) in the Sequenced Treatment Alternatives to Relieve Depression study, including 2158 participants with MDD without comorbid PTSD and 122 participants with MDD with comorbid PTSD (MDD + PTSD)...
October 18, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764050/a-pilot-study-of-randomized-head-to-head-of-metformin-versus-topiramate-in-obese-people-with-schizophrenia
#6
Po-Jui Peng, Pei-Shen Ho, Chia-Kuang Tsai, San-Yuan Huang, Chih-Sung Liang
OBJECTIVES: A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The study aims to evaluate and compare the efficacy of metformin and topiramate in weight reduction and weight maintenance after discontinuation of these drugs in obese people with schizophrenia...
October 18, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27755134/the-effect-of-l-dopa-carbidopa-intestinal-gel-in-parkinson-disease-assessed-using-neurophysiologic-techniques
#7
Matteo Bologna, Anna Latorre, Francesca Di Biasio, Antonella Conte, Daniele Belvisi, Nicola Modugno, Antonio Suppa, Alfredo Berardelli, Giovanni Fabbrini
BACKGROUND: By providing a stable and smooth L-dopa plasmatic level, L-dopa/carbidopa intestinal gel reproduces the physiological continuous dopaminergic receptor stimulation in patients with Parkinson disease (PD), and it therefore represents a suitable tool to investigate the role of the altered dopaminergic neurotransmission in the pathophysiology of motor and sensory abnormalities in this condition. METHODS: We studied 11 patients with advanced PD being treated with L-Dopa/carbidopa intestinal gel (LCIG) and 11 age-matched healthy subjects...
October 14, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27755132/spermatorrhea-and-loss-of-libido-induced-by-topiramate-first-case-report-and-review-of-literature
#8
Mengqian Wu, Nanya Hao, Dong Zhou
BACKGROUND: Topiramate (TPM) is a broad-spectrum antiepileptic drug used for a variety of clinical conditions, including migraine prophylaxis and mood disorders. Spermatorrhea accompanied by loss of libido severely lowers quality of life for men, but had never been reported as a possible adverse effect of TPM. CASE PRESENTATION: Here, we present a case of a 39-year-old Chinese man who was diagnosed with partial epilepsy and treated with TPM (100 mg/d). Eleven days after initiating TPM treatment, he began to experience spermatorrhea every 2 to 3 days, accompanied by loss of libido, lack of energy, lassitude, irascibility, weakness, poor appetite, frequent urination, and nocturia...
October 14, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27755131/a-case-of-restless-legs-syndrome-related-to-opioid-discontinuation
#9
Grace H Lee, Alejandro V Jaen-Vinuales, Jonathan T Stewart
No abstract text is available yet for this article.
October 14, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27753696/antiepileptic-drugs-under-investigation-for-treatment-of-focal-epilepsy
#10
Pasquale Striano, Vincenzo Belcastro, Antonietta Coppola, Carlo Minetti, Salvatore Striano
INTRODUCTION: Despite optimal medical treatment, up to 30% of patients with epilepsy continue to experience recurrent seizures, and the challenge for new more efficacious and better-tolerated drugs is continuing. New antiepileptic drugs include the evolution of preexisting drugs and new compounds identified through the investigation of additional molecular targets, such as SV2A synaptic vesicle protein, voltage-gated potassium channels, ionotropic and metabotropic glutamate receptors, and gap junctions...
October 5, 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27828814/recurrent-and-alternating-pisa-syndrome-a-surprising-entity
#11
Michel Sáenz-Farret, Alejandro Pellene, Federico Micheli
No abstract text is available yet for this article.
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764053/escitalopram-associated-acute-urinary-retention-in-elderly-men-with-known-or-latent-benign-prostatic-hyperplasia-a-case-series
#12
Panagiotis Ferentinos, Dimitrios Margaritis, Athanasios Douzenis
Lower urinary tract outflow dysfunction is frequent in older men and a potential cause of serious complications such as acute urinary retention (AUR). Drug-induced AUR has only rarely been reported with selective serotonin reuptake inhibitors including escitalopram; reported cases had no history of urinary outflow dysfunction. We herein report the development of AUR after the introduction of escitalopram at a standard dose in 3 male patients with previously diagnosed or unknown/latent and nonsymptomatic benign prostatic hyperplasia...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27764052/a-case-of-resistant-schizophrenia-successfully-treated-with-clozapine-long-acting-injectable-aripiprazole-combination
#13
Gianna Sepede, Giuseppe Di Iorio, Maria Chiara Spano, Marco Lorusso, Fabiola Sarchione, Rita Santacroce, Rosa Maria Salerno, Massimo Di Giannantonio
BACKGROUND: Treatment-resistant schizophrenia (TRS) is a condition characterized by intense symptom severity and poor response to different antipsychotic agents. The first therapeutic option in TRS is clozapine, but often high/medium doses are not tolerated. Adding an oral antipsychotic to low doses of clozapine is a promising strategy in the management of TRS. On the contrary, there are few data on combined clozapine/long-acting injectable (LAI) medications, and none on clozapine/LAI-aripiprazole...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27755133/hemifacial-spasm-from-lyme-disease-antibiotic-treatment-points-to-the-cause
#14
Tessa M LeWitt
A wide range of etiologies can cause hemifacial spasm (HFS), including infection. In this case report, a 44-year-old woman developed HFS and was explored surgically 7 years later. No abnormalities were found. Afterward, treatment of a surgical wound infection with an oral cephalosporin resulted in a temporary HFS remission that had never occurred previously. This antibiotic experience prompted further workup for an underlying infection, which ultimately led to diagnosis of Lyme disease. Presentation of HFS due to Lyme disease has not been reported...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27563745/baclofen-in-the-therapeutic-of-sequele-of-traumatic-brain-injury-spasticity
#15
Adán Pérez-Arredondo, Eduardo Cázares-Ramírez, Paul Carrillo-Mora, Marina Martínez-Vargas, Noemí Cárdenas-Rodríguez, Elvia Coballase-Urrutia, Radamés Alemón-Medina, Aristides Sampieri, Luz Navarro, Liliana Carmona-Aparicio
Traumatic brain injury (TBI) is an alteration in brain function, caused by an external force, which may be a hit on the skull, rapid acceleration or deceleration, penetration of an object, or shock waves from an explosion. Traumatic brain injury is a major cause of morbidity and mortality worldwide, with a high prevalence rate in pediatric patients, in which treatment options are still limited, not available at present neuroprotective drugs. Although the therapeutic management of these patients is varied and dependent on the severity of the injury, general techniques of drug types are handled, as well as physical and surgical...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27482955/encephalitis-with-antibodies-to-glun2b-during-administration-of-clozapine
#16
Junji Gon, Yasushi Takehisa, Yuji Yada, Yoshiki Kishi, Etsuko Oshima, Yukitoshi Takahashi, Manabu Takaki
Clozapine's immunomodulatory properties may contribute to its effect on schizophrenia as well as various adverse effects. However, a possible relationship between N-methyl-D-aspartate-type glutamate receptor antibodies, refractory schizophrenia, and clozapine has not been reported. We experienced a patient who developed refractory schizophrenia that mimicked an exacerbation of encephalitis with antibodies to N-methyl-D-aspartate-type glutamate receptor (GluN2B) after administration of clozapine for 26 days...
November 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27466724/a-case-of-disulfiram-induced-psychosis-in-a-previously-asymptomatic-patient-maintained-on-mixed-amphetamine-salts-a-review-of-the-literature-and-possible-pathophysiological-explanations
#17
David R Spiegel, Aidan McCroskey, Kapaakea Puaa, Grant Meeker, Lauren Hartman, Joshua Hudson, Yu C Hung
Although perhaps better known as an irreversible aldehyde dehydrogenase inhibitor causing increased acetaldehyde levels after concomitant intake of ethanol, disulfiram or one of its metabolites (diethyldithiocarbamate) also inhibit dopamine β-hydroxylase, an enzyme that converts dopamine to norepinephrine. This mechanism has been advanced as a possible explanation for the development of psychosis, during disulfiram treatment, either in monotherapy or in combination therapy, when interaction-emergent psychosis could be causal...
September 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27454391/premenstrual-dysphoric-disorder-without-comorbid-psychiatric-conditions-a-systematic-review-of-therapeutic-options
#18
Gianna Sepede, Fabiola Sarchione, Ilaria Matarazzo, Massimo Di Giannantonio, Rosa Maria Salerno
OBJECTIVES: Premenstrual dysphoric disorder (PMDD) is a disabling condition affecting approximately 2% to 8% of women during reproductive age. It has been recently included in the mood disorder section of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, but its treatment as a primary psychiatric illness is still debated, because of the high prevalence of other mental disturbances in PMDD patients. On the other hand, clear clinical guidelines for PMDD patients not suffering from comorbid mental conditions are not yet available...
September 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27454389/asynchronicity-of-organic-and-psychiatric-symptoms-in-a-case-of-sertraline-intoxication
#19
Mariabernarda Pitzianti, Sara Marciano, Maurizio Minnei, Antonia Baratta, Augusto Pasini
Sertraline is a selective serotonin reuptake inhibitor used as an antidepressant and antipanic agent in children and adolescents. Sertraline is well tolerated and its safety profile in overdose is favorable. However, sertraline overdose may cause a toxic hyperserotonergic state known as serotonin syndrome (SS). Serotonin syndrome may be misdiagnosed in children because it has been reported mostly in adults. In the present case report, we describe a 16-year-old female patient who ingested 2000 mg of sertraline to attempt suicide...
September 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27438181/comparison-of-selegiline-and-rasagiline-therapies-in-parkinson-disease-a-real-life-study
#20
Chava Peretz, Hagar Segev, Violet Rozani, Tanya Gurevich, Baruch El-Ad, Judith Tsamir, Nir Giladi
BACKGROUND: We aimed to compare indicators of Parkinson disease (PD) progression between patients first prescribed either selegiline or rasagiline as their antiparkinsonian drugs (APDs) on the basis of real-life data. METHODS: Pharmacy data on members of a large Israeli health maintenance organization, treated as patients with PD during 2001-2012 and prescribed selegiline or rasagiline as their first APD, were analyzed. The first APD was selegiline for 349 patients (2001-2006) and rasagiline for 485 patients (2007-2012)...
September 2016: Clinical Neuropharmacology
journal
journal
26752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"